Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Non Operating Income (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Non Operating Income for 6 consecutive years, with $30000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 99.67% to $30000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.5 million through Dec 2025, up 19.04% year-over-year, with the annual reading at -$776000.0 for FY2025, 102.23% down from the prior year.
  • Non Operating Income for Q4 2025 was $30000.0 at Relay Therapeutics, down from $6.2 million in the prior quarter.
  • The five-year high for Non Operating Income was $9.0 million in Q4 2024, with the low at -$24000.0 in Q4 2022.
  • Average Non Operating Income over 5 years is $2.4 million, with a median of $201000.0 recorded in 2021.
  • The sharpest move saw Non Operating Income plummeted 177.78% in 2023, then surged 897400.0% in 2024.
  • Over 5 years, Non Operating Income stood at $830000.0 in 2021, then tumbled by 102.89% to -$24000.0 in 2022, then soared by 104.17% to $1000.0 in 2023, then soared by 897400.0% to $9.0 million in 2024, then tumbled by 99.67% to $30000.0 in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $30000.0, $6.2 million, and $6.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.